OxSonics Launches New Website & Renames as OxSonics Therapeutics

Oxford, UK – 7th January 2019 – OxSonics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer today announced the launch of its new website and its new name “OxSonics Therapeutics”. Colin Story, CEO, commented: “OxSonics Therapeutics innovative drug delivery platform is designed to deliver significant therapeutic advantages to those […]

OxSonics’ Cofounder Professor Coussios Presents at the Royal Society

Oxford, UK – 24th October 2018 – OxSonics cofounder and Chief Technology Officer Professor Constantin Coussios is an invited speaker at a scientific meeting of the Royal Society on the subject of “Delivering novel therapies in the 21st century”. Professor Coussios’ talk entitled “Shaken and Stirred: Ultrasound-enhanced Drug Delivery” will include data generated using OxSonics proprietary drug delivery platform […]

OxSonics to Present at the International Oncolytic Virus Congress 2018

Oxford, UK – 12th April 2018 – OxSonics co-founder Professor Robert Carlisle is an invited speaker at the 2018 International Oncolytic Virus Congress and will be speaking on the subject of “Enhanced Delivery of Oncolytic Viruses into and Throughout Tumours”. The congress is attended by the world’s leading academic groups and companies developing ground-breaking oncolytic viral therapies. Presentations […]

Publication: SonoTran® Doesn’t Affect the Inherent Activity of Oncology Drugs

Oxford, UK – 10th January 2018 – OxSonics Limited, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer patients, today reported that a paper entitled “Ultrasound-mediated cavitation does not decrease the activity of small molecule, antibody or viral-based medicines” was published in the International Journal of Nanomedicine. The publication evidences the fact that […]

Glyn Edwards MBE Joins OxSonics’ Board as Non-Executive Director

Oxford, UK – 25th October 2017 – OxSonics Limited, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer patients, today announced that Glyn Edwards is to join the board as Non-Executive Director. Glyn Edwards has held the position of CEO of Summit plc since April 2012 where he […]